{"id":"W2973037195","doi":"10.1016/s1474-4422(19)30283-2","title":"Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute on Aging; Johnson and Johnson Pharmaceutical Research and Development; Fuel Cell Technologies Program; Fifth Framework Programme; Canadian Institutes of Health Research; Parkinsonfonden; Danone Research Centre for Specialised Nutrition; European Regional Development Fund; European Research Council; GE Healthcare; Fondation Segré; H. Lundbeck A/S; Marcus och Amalia Wallenbergs minnesfond; National Institute of Biomedical Imaging and Bioengineering; Amsterdam Neuroscience; Skånes universitetssjukhus; Pfizer Pharmaceuticals; Innovative Medicines Initiative; AXA Research Fund; Fondation Plan Alzheimer; Servier; American Liver Foundation; Knut och Alice Wallenbergs Stiftelse; Australian Government; Lunds Universitet; Vetenskapsrådet; NIHR Imperial Biomedical Research Centre; Foundation for the National Institutes of Health; Eisai; UCLH Biomedical Research Centre; Fondation pour la Recherche sur la Biodiversite; Hôpitaux Universitaires de Genève; Fondation Vaincre Alzheimer; Bundesministerium für Bildung und Forschung; Alzheimer Nederland; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Institut National de la Santé et de la Recherche Médicale; Boehringer Ingelheim; Seventh Framework Programme; Novartis Pharmaceuticals Corporation; Merck; Association pour la Recherche sur le Cancer; DoD Alzheimer's Disease Neuroimaging Initiative; Alzheimer's Disease Neuroimaging Initiative; Meso Scale Diagnostics; Biogen; Agence Nationale de la Recherche; F. Hoffmann-La Roche; Alzheimer's Association; European Federation of Pharmaceutical Industries and Associations; Takeda Pharmaceutical Company; Hjärnfonden; AstraZeneca; European Commission; AbbVie; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Novartis; Bristol-Myers Squibb; Eli Lilly and Company; Roche; ZonMw; National Institutes of Health; Alzheimer's Drug Discovery Foundation; Nederlandse Brandwonden Stichting; National Science Foundation; Fundação para a Ciência e a Tecnologia; EU Joint Programme – Neurodegenerative Disease Research; Oryzon Genomics; Sweden-America Foundation","keywords":"Dementia; Biomarker; Oncology; Medicine; Cohort; Alzheimer's Disease Neuroimaging Initiative; Internal medicine; Disease; Gerontology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008980106,0.001716686,0.0017904,0.0009346401,0.0006925169,0.002293226,0.002532118,0.002533543,0.003295333],"category_scores_gemma":[0.01972773,0.000902144,0.004321999,0.00126606,0.0005996765,0.001537078,0.001509662,0.002484653,0.0007478736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001740031,"about_ca_system_score_gemma":0.001438814,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04273356,"about_ca_topic_score_gemma":0.02156338,"domain_scores_codex":[0.9979752,0.001260574,0.0001003619,0.0003601185,0.0001068894,0.0001968993],"domain_scores_gemma":[0.9834403,0.01195935,0.00151509,0.001767004,0.0007351369,0.0005829858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.05668133,0.007689221,0.7218167,0.001341419,0.02206562,0.001304664,0.002577214,0.1341083,0.001073391,0.008778702,0.008804875,0.0337587],"study_design_scores_gemma":[0.005420113,0.007885105,0.4007718,0.0006067799,0.01456664,0.0009219052,0.001507286,0.5462927,0.0005185848,0.01703614,0.004085534,0.0003874875],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919192,0.000722685,0.003300866,0.0005648629,0.00004793886,0.00007307433,0.002526588,0.00005795509,0.0007869556],"genre_scores_gemma":[0.9954334,0.000334233,0.001511768,0.00009872083,0.00002719811,0.0001133519,0.001660413,0.00001491978,0.0008060514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04273356,"threshold_uncertainty_score":0.08496964,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05165167316379238,"score_gpt":0.332468020614417,"score_spread":0.2808163474506246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}